Massachusetts, US-based clinical-stage biopharmaceutical firm Zenas BioPharma has closed an upsized $200-million Series C round of financing to advance mid- and late-stage immunology-focused clinical development programmes.
Continue Reading: Unlock Free Insights!
Stay updated with 3 free articles every month
Access our exclusive newsletters delivered to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
